FDA bets on AI and cloud monitoring for clinical trials as it looks to rebuild after DOGE layoffs

THE DECODER / 4/30/2026

📰 NewsDeveloper Stack & InfrastructureSignals & Early TrendsIndustry & Market MovesModels & Research

共有:

Key Points

The FDA is launching a pilot program to monitor clinical trials in real time using AI and cloud computing capabilities.
The agency says this approach could significantly reduce the time required to review and approve new drugs.
The initiative is positioned as part of the FDA’s broader rebuilding efforts following DOGE-related layoffs.
By shifting monitoring to real-time AI/cloud workflows, the FDA aims to improve visibility and responsiveness across the clinical trial lifecycle.

Lots of pills on a table

The FDA is launching a pilot program to monitor clinical trials in real time using AI and cloud computing, a move the agency says could dramatically shorten the time it takes to approve new drugs.

The article FDA bets on AI and cloud monitoring for clinical trials as it looks to rebuild after DOGE layoffs appeared first on The Decoder.